Analysis of Multitarget Activities and Assay Interference Characteristics of Pharmaceutically Relevant Compounds

The availability of large amounts of data in public repositories provide a useful source of knowledge in the field of drug discovery. Given the increasing sizes of compound databases and volumes of activity data, computational data mining can be used to study different characteristics and properties of compounds on a large scale. One of the major source of identification of new compounds in early phase of drug discovery is high-throughput screening where millions of compounds are tested against many targets. The screening data provides opportunities to assess activity profiles of compounds. This thesis aims at systematically mining activity data from publicly available sources in order to study the nature of growth of bioactive compounds, analyze multitarget activities and assay interference characteristics of pharmaceutically relevant compounds in context of polypharmacology. In the first study, growth of bioactive compounds against five major target families is monitored over time and compound-scaffold-CSK (cyclic skeleton) hierarchy is applied to investigate structural diversity of active compounds and topological diversity of their scaffolds. The next part of the thesis is based on the analysis of screening data. Initially, extensively assayed compounds are mined from the PubChem database and promiscuity of these compounds is assessed by taking assay frequencies into account. Next, DCM (dark chemical matter) or consistently inactive compounds that have been extensively tested are systematically extracted and their analog relationships with bioactive compounds are determined in order to derive target hypotheses for DCM. Further, PAINS (pan-assay interference compounds) are identified in the extensively tested set of compounds using substructure filters and their assay interference characteristics are studied. Finally, the limitations of PAINS filters are addressed using machine learning models that can distinguish between promiscuous and DCM PAINS. Structural context dependence of PAINS activities is studied by assessing predictions through feature weighting and mapping

Chemoinformatics-Driven Approaches for Kinase Drug Discovery

Given their importance for the majority of cell physiology processes, protein kinases are among the most extensively studied protein targets in drug discovery. Inappropriate regulation of their basal levels results in pathophysiological disorders. In this regard, small-molecule inhibitors of human kinome have been developed to treat these conditions effectively and improve the survival rates and life quality of patients. In recent years, kinase-related data has become increasingly available in the public domain. These large amounts of data provide a rich knowledge source for the computational studies of kinase drug discovery concepts. This thesis aims to systematically explore properties of kinase inhibitors on the basis of publicly available data. Hence, an established "selectivity versus promiscuity" conundrum of kinase inhibitors is evaluated, close structural analogs with diverging promiscuity levels are analyzed, and machine learning is employed to classify different kinase inhibitor binding modes. In the first study, kinase inhibitor selectivity trends are explored on the kinase pair level where kinase structural features and phylogenetic relationships are used to explain the obtained selectivity information. Next, selectivity of clinical kinase inhibitors is inspected on the basis of cell-based profiling campaign results to consolidate the previous findings. Further, clinical candidates are mapped to medicinal chemistry sources and promiscuity levels of different inhibitor subsets are estimated, including designated chemical probes. Additionally, chemical probe analysis is extended to expert-curated representatives to correlate the views established by scientific community and evaluate their potential for chemical biology applications. Then, large-scale promiscuity analysis of kinase inhibitor data combining several public repositories is performed to subsequently explore promiscuity cliffs (PCs) and PC pathways and study structure-promiscuity relationships. Furthermore, an automated extraction protocol prioritizing the most informative pathways is proposed with focus on those containing promiscuity hubs. In addition, the generated promiscuity data structures including cliffs, pathways, and hubs are discussed for their potential in experimental and computational follow-ups and subsequently made publicly available. Finally, machine learning methods are used to develop classification models of kinase inhibitors with distinct experimental binding modes and their potential for the development of novel therapeutics is assessed

Computational prediction of metabolism: sites, products, SAR, P450 enzyme dynamics, and mechanisms.

Metabolism of xenobiotics remains a central challenge for the discovery and development of drugs, cosmetics, nutritional supplements, and agrochemicals. Metabolic transformations are frequently related to the incidence of toxic effects that may result from the emergence of reactive species, the systemic accumulation of metabolites, or by induction of metabolic pathways. Experimental investigation of the metabolism of small organic molecules is particularly resource demanding; hence, computational methods are of considerable interest to complement experimental approaches. This review provides a broad overview of structure- and ligand-based computational methods for the prediction of xenobiotic metabolism. Current computational approaches to address xenobiotic metabolism are discussed from three major perspectives: (i) prediction of sites of metabolism (SOMs), (ii) elucidation of potential metabolites and their chemical structures, and (iii) prediction of direct and indirect effects of xenobiotics on metabolizing enzymes, where the focus is on the cytochrome P450 (CYP) superfamily of enzymes, the cardinal xenobiotics metabolizing enzymes. For each of these domains, a variety of approaches and their applications are systematically reviewed, including expert systems, data mining approaches, quantitative structure-activity relationships (QSARs), and machine learning-based methods, pharmacophore-based algorithms, shape-focused techniques, molecular interaction fields (MIFs), reactivity-focused techniques, protein-ligand docking, molecular dynamics (MD) simulations, and combinations of methods. Predictive metabolism is a developing area, and there is still enormous potential for improvement. However, it is clear that the combination of rapidly increasing amounts of available ligand- and structure-related experimental data (in particular, quantitative data) with novel and diverse simulation and modeling approaches is accelerating the development of effective tools for prediction of in vivo metabolism, which is reflected by the diverse and comprehensive data sources and methods for metabolism prediction reviewed here. This review attempts to survey the range and scope of computational methods applied to metabolism prediction and also to compare and contrast their applicability and performance.JK, MJW, JT, PJB, AB and RCG thank Unilever for funding

UNDERSTANDING CONDITIONAL MODES OF ACTIONS IN CHEMICAL-INDUCED TOXICITY USING RULE MODELS

It is estimated that 115 million animals are used in experimental testing each year. Hence, shifting efforts toward alternative methods for toxicity assessment is essential. However, slow regulatory acceptance of new approaches is governed by knowledge gaps in toxicity modes of action. In this thesis, I describe these challenges and the use of in vitro screening as an alternative of animal testing. I also discuss common data-based methods to derive hypotheses about toxicity modes of actions, and the associated limitations in capturing multiple biological perturbations. I applied novel data-based workflows, using rule models, to prioritize in vitro assays predictive of toxicity as well as to detect significant polypharmacology profiles. I explain how constraints were applied to rule-based models to inform meaningful mechanistic interpretation for two toxicity endpoints: rat hepatotoxicity and acute toxicity. I compared assays selected, by rules, for predicting hepatotoxicity with endpoints used in in vitro models from commercial sources. An overlap was observed including cytochrome activity, mitochondrial toxicity and immunological responses. However, nuclear receptor activity, identified in rules, is not currently covered in commercial setups. I also demonstrate that endocrine disruption endpoints extrapolate better into in vivo toxicity when a set of specific conditions are met, such as physicochemical properties associated with good bioavailability. Next, I examined synergistic interactions between conditions in rules describing acute toxicity. I gained novel insights into how specific stressors potentiate the perturbation by known key events, such as acetylcholinesterase inhibition and neuro-signalling disruption. I show that examining polypharmacology profiles is particularly important at low bioactive potencies. Further, the overall predictive performance of rules describing acute toxicity was tested against a benchmark Random Forest model in a conformal prediction framework. Irrespective to the data type used in the training, the models were prone to bias over compounds promiscuity, by which high promiscuous compounds were more likely to be predicted as toxic. Overall, the studies conducted in this thesis provide novel insights into molecular mechanisms of toxicity, namely hepatotoxicity and acute toxicity, and with regards to chemical properties and polypharmacology. This knowledge can be used to improve the utility and design of alternative methods for toxicity, and hence, accelerate the regulatory acceptance.Islamic Development Bank Cambridge Trust Fun

Binding site matching in rational drug design: Algorithms and applications

© 2018 The Author(s) 2018. Published by Oxford University Press. All rights reserved. Interactions between proteins and small molecules are critical for biological functions. These interactions often occur in small cavities within protein structures, known as ligand-binding pockets. Understanding the physicochemical qualities of binding pockets is essential to improve not only our basic knowledge of biological systems, but also drug development procedures. In order to quantify similarities among pockets in terms of their geometries and chemical properties, either bound ligands can be compared to one another or binding sites can be matched directly. Both perspectives routinely take advantage of computational methods including various techniques to represent and compare small molecules as well as local protein structures. In this review, we survey 12 tools widely used to match pockets. These methods are divided into five categories based on the algorithm implemented to construct binding-site alignments. In addition to the comprehensive analysis of their algorithms, test sets and the performance of each method are described. We also discuss general pharmacological applications of computational pocket matching in drug repurposing, polypharmacology and side effects. Reflecting on the importance of these techniques in drug discovery, in the end, we elaborate on the development of more accurate meta-predictors, the incorporation of protein flexibility and the integration of powerful artificial intelligence technologies such as deep learning

Associating adverse drug effects with protein targets by integrating adverse event, in vitro bioactivity, and pharmacokinetic data

Adverse drug effects are unintended and undesirable effects of medicines, causing attrition of molecules in drug development and harm to patients. To anticipate potential adverse effects early, drug candidates are commonly screened for pharmacological activity against a panel of protein targets. However, there is a lack of large-scale, quantitative information on the links between routinely screened proteins and the reporting of adverse events (AEs). This work describes a systematic analysis of associations between AEs observed in humans and bioactivities of drugs while taking into account drug plasma concentrations. In the first chapter, post-marketing drug-AE associations are derived from the United States Food and Drug Administration Adverse Event Reporting System using disproportionality methods, while applying Propensity Score Matching to reduce confounding factors. The resulting drug-AE associations are compared to those from the Side Effect Resource, which are primarily derived from clinical trials. The analysis reveals that the datasets generally share less than 10% of reported AEs for the same drug and have different distributions of AEs across System Organ Classes (SOCs). Using the drugs from the two AE datasets described in the first chapter, the second chapter integrates corresponding bioactivities, i.e. measured potencies and affinities from the ChEMBL database and ligand-based target predictions obtained with the tool PIDGIN, with drug plasma concentrations compiled from literature, such as Cmax. Compared to a constant bioactivity cut-off of 1 uM, using the ratio of the unbound drug plasma concentration over the drug potency, i.e. Cmax/XC50, results in different binary activity calls for protein targets. Whether deriving activity calls in this way results in the selection of targets with greater relevance to human AEs is investigated in the third chapter, which computes relationships between targets and AEs using different measures of statistical association. Using the Cmax/XC50 ratio results in higher Likelihood Ratios and Positive Predictive Values (PPVs) for target-AE associations that were previously reported in the context of secondary pharmacology screening, at the cost of a lower recall, possibly due to the smaller size of the dataset with available plasma concentrations. Furthermore, a large-scale quantitative assessment of bioactivities as indicators of AEs reveals a trade-off between the PPV and how many AE-associated drugs can potentially be detected from in vitro screening, although using combinations of targets can improve the detection rate in ~40% of cases at limited cost to the PPV. The work highlights AEs most strongly related to bioactivities and their SOC distribution. Overall, this thesis contributes to knowledge of the relationships between in vitro bioactivities and empirical evidence of AEs in humans. The results can inform the selection of proteins for secondary pharmacology screening and the development of computational models to predict AEs.Lhasa Limite

Computational Methods Generating High-Resolution Views of Complex Structure-Activity Relationships

The analysis of structure-activity relationships (SARs) of small bioactive compounds is a central task in medicinal chemistry and pharmaceutical research. The study of SARs is in principle not limited to computational methods, however, as data sets rapidly grow in size, advanced computational approaches become indispensable for SAR analysis. Activity landscapes are one of the preferred and widely used computational models to study large-scale SARs. Activity cliffs are cardinal features of activity landscape representations and are thought to contain high SAR information content. This work addresses major challenges in systematic SAR exploration and specifically focuses on the design of novel activity landscape models and comprehensive activity cliff analysis. In the first part of the thesis, two conceptually different activity landscape representations are introduced for compounds active against multiple targets. These models are designed to provide an intuitive graphical access to compounds forming single and multi-target activity cliffs and displaying multi-target SAR characteristics. Further, a systematic analysis of the frequency and distribution of activity cliffs is carried out. In addition, a large-scale data mining effort is designed to quantify and analyze fingerprint-dependent changes in SAR information. The second part of this work is dedicated to the concept of activity cliffs and their utility in the practice of medicinal chemistry. Therefore, a computational approach is introduced to search for detectable SAR advantages associated with activity cliffs. In addition, the question is investigated to what extent activity cliffs might be utilized as starting points in practical compound optimization efforts. Finally, all activity cliff configurations formed by currently available bioactive compounds are thoroughly examined. These configurations are further classified and their frequency of occurrence and target distribution are determined. Furthermore, the activity cliff concept is extended to explore the relation between chemical structures and compound promiscuity. The notion of promiscuity cliffs is introduced to deduce structural modifications that might induce large-magnitude promiscuity effects

Development and Interpretation of Machine Learning Models for Drug Discovery

In drug discovery, domain experts from different fields such as medicinal chemistry, biology, and computer science often collaborate to develop novel pharmaceutical agents. Computational models developed in this process must be correct and reliable, but at the same time interpretable. Their findings have to be accessible by experts from other fields than computer science to validate and improve them with domain knowledge. Only if this is the case, the interdisciplinary teams are able to communicate their scientific results both precisely and intuitively. This work is concerned with the development and interpretation of machine learning models for drug discovery. To this end, it describes the design and application of computational models for specialized use cases, such as compound profiling and hit expansion. Novel insights into machine learning for ligand-based virtual screening are presented, and limitations in the modeling of compound potency values are highlighted. It is shown that compound activity can be predicted based on high-dimensional target profiles, without the presence of molecular structures. Moreover, support vector regression for potency prediction is carefully analyzed, and a systematic misprediction of highly potent ligands is discovered. Furthermore, a key aspect is the interpretation and chemically accessible representation of the models. Therefore, this thesis focuses especially on methods to better understand and communicate modeling results. To this end, two interactive visualizations for the assessment of naive Bayes and support vector machine models on molecular fingerprints are presented. These visual representations of virtual screening models are designed to provide an intuitive chemical interpretation of the results